跳至主要内容
临床试验/EUCTR2022-003325-22-NL
EUCTR2022-003325-22-NL进行中(未招募)1 期

The immunomodulatory effect of sugammadex after total hip replacement surgery under neuraxial anaesthesia: a pilot study - MAGIC study

RadboudUMC0 个研究点目标入组 20 人开始时间: 2022年11月7日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
RadboudUMC
入组人数
20

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • - Age of 18 years or older
  • - Scheduled for total hip replacement surgery under neuraxial surgery
  • - Scheduled for primary hip replacement surgery
  • - Informed consent obtained
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 10
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 10

排除标准

  • - Insufficient control of the Dutch language to read the patient information and to fill out de questionnaires
  • - Known or suspected hypersensitivity to sugammadex
  • - Deficiency of vitamin K dependent clotting factors or coagulopathy
  • - Severe renal disease (creatinine clearance <30 ml/min), including patients on dialysis)
  • - Severe liver disease (Child-Pugh Classification C)
  • - Women who are or may be pregnant or currently breastfeeding
  • - Severe vertebral column disorder
  • - Chronic use of psychotropic drugs
  • - Known hypertrophic obstructive cardiomyopathy, severe aortic valve stenosis or severe mitral valve stenosis
  • - Use of immunomodulatory medication

研究者

发起方
RadboudUMC

相似试验